About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72721 record(s)
Req # A-2023-001438
Records regarding all funding allocated by Health Canada for LGBTQ+-specific mental health and/or suicide prevention initiatives in the past three fiscal years. Details of any research, studies, or surveys conducted by or on behalf of Health Canada…Organization: Health Canada
August 2024
Req # A-2023-001443
The cover letter which accompanied the Abbreviated New Drug Submission (ANDS) for Aripiprazole for which an ANDS was added to the Health Canada List of Generic Submissions Under Review (GSUR) on January 19, 2024. Screening Acceptance letter for the…Organization: Health Canada
August 2024
Req # A-2023-001460
The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Third Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001462
The most recent Certified Product Information Document (CPID) submitted for the Third Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001485
The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Degarelix Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001546
Medical Ingredient: "Ruxolitinib phosphate" Therapeutic Area: "Antineoplastic agents" Number of submissions under review: "1". The year and month in which the following submission was accepted for review; and the…Organization: Health Canada
August 2024
Req # A-2023-001555
All documents from October 1, 2022, to March 12, 2024, respecting the invitation, scheduling and appearance of Cameron MacDonald, Antonio Utano, Minh Doan and David Yeo before the House of Commons Standing Committee on Government Operations and…Organization: Health Canada
August 2024
Req # A-2023-001605
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Semaglutide ANDS.Organization: Health Canada
August 2024
Req # A-2023-001608
Global Health Imports Corporation's medical device establishment licence, including the date it was issued and the date it was revoked.Organization: Health Canada
August 2024
Req # A-2023-001612
The name of the company who submitted the Semaglutide Abbreviated New Drug Submission (ANDS), and the year and month in which the Semaglutide ANDS was accepted for review.Organization: Health Canada
August 2024